ASSOCIATION OF THE SEH GENE PROMOTER POLYMORPHISMS AND HAPLOTYPES WITH PREECLAMPSIA

Association of the EPHX2 promoter polymorphisms and preeclampsia

  • İsmail Sarı Department of Medical Biochemistry, Faculty of Medicine, Nigde Omer Halis Demir University,
DOI: https://doi.org/10.5937/jomb0-27745
Ključne reči: Epoxyeicosatrienoic acids; preeclampsia; soluble epoxide hydrolase; polymorphism, gene promoter

Sažetak


Background: The epoxyeicosatrienoic acids (EETs) have antihypertensive, anti-inflammatory, and organ protective properties, and their circulation levels are related to hypertension, diabetes mellitus, cardiovascular diseases, and preeclampsia. Soluble epoxide hydrolase (sEH) catalyzes the degradation of EETs to less biologically active dihydroxyeicosatrienoic acids. Here we sequenced the promoter region of EPHX2 to investigate the association between promoter sequence alterations that we thought to affect the expression levels of the enzyme and preeclampsia (PE).

Methods: Nucleotide sequencing of the promoter region of the EPHX2, spanning from position −671 to +30, was performed on 100 pregnant women with PE and, 20 or more weeks pregnant normotensive, healthy women (n=100)

Results: Pregnant women who carry rs4149235, rs4149232, rs73227309, and rs62504268 polymorphisms have 4.4, 2.4, 2.3, and 2.8 times significantly increased risk of PE, respectively. CCGG (OR: 3.11; 95% CI: 1.12-8.62) and CCCA (OR: 0.45; 95 % CI: 0.36-0.55) haplotypes were associated with an increased and decreased risk of PE, respectively.

Conclusions: Four SNPs (rs4149232, rs4149235, rs73227309, and rs62504268) in the promoter region of the EPHX2, and CCGG and CCCA haplotypes of these 4 SNPs were significantly associated with PE. These SNPs in the promoter region may affect sEH expression and thus enzyme activity and may play a role in PE pathogenesis by causing individual differences in EET levels. However, future studies are needed to confirm our findings and examine the effect of these SNPs on the sEH expression and/or enzyme activity.

Reference

1. August P, Sibai BM. Preeclampsia: clinical features and diagnosis. UpToDate 2019.
2. Wang A, Rana S, Karumanchi SA. Preeclampsia: the role of angiogenic factors in its pathogenesis. Physiology 2009; 24(3): 147-158.
3. Giachini FR, Galaviz-Hernandez C, Damiano AE, et al. Vascular Dysfunction in Mother and Offspring During Preeclampsia: Contributions from Latin-American Countries. Current hypertension reports 2017; 19(10): 83
4. Morgan T, Ward K. New insights into the genetics of preeclampsia. Semin Perinatol 1999; 23: 14–23.
5. Rajendran P, Rengarajan T, Thangavel J, et al. The vascular endothelium and human diseases. International journal of biological sciences 2013; 9(10): 1057.
6. Node K, Huo Y, Ruan X, et al. Anti-inflammatory properties of cytochrome P450 epoxygenase- derived eicosanoids. Science 1999; 285: 1276-1279.
7. Fisslthaler B, Popp R, Kiss L, et al. Cytochrome P450 2C is an EDHF synthase in coronary arteries. Nature 1999; 401: 493–497.
8. Fava C, Ricci M, Melander O, et al. Hypertension, cardiovascular risk and polymorphisms in genes co ntrolling the cytochrome P450 pathway of arachidonic acid: A sex-specific relation? Prostaglandins Other Lipid Mediat 2012; 98(3-4): 75-85.
9. Zheng X, Zinkevich NS, Gebremedhin D, et al. Arachidonic Acid–Induced Dilation in Human Coronary Arterioles: Convergence of Signaling Mechanisms on Endothelial TRPV4-Mediated Ca2+ Entry. J Am Heart Assoc 2013; 2(3): e000080.
10. Liu X, Wu J, Liu H, et al. Disturbed ratio of renal 20-HETE/EETs is involved in androgen-induced hypertension in cytochrome P450 4F2 transgenic mice. Gene 2012; 505 (2): 352–359.
11. Lee CR, North KE, Bray MS, et al. Genetic variation in soluble epoxide hydrolase (ephx2) and risk of coronary heart disease: the atherosclerosis risk in communities (aric) study. Hum Mol Genet 2006; 15: 1640–1649.
12. Fava C, Montagnana M, Danese E, et al. Homozygosity for the EPHX2 K55R polymorphism increases the long-term risk of ischemic stroke in men: a study in Swedes. Pharmacogenet Genomics 2010; 20(2): 94-103.
13. Kompa AR, Wang BH, Xu G, et al. Soluble epoxide hydrolase inhibition exerts beneficial anti-remodeling actions post-myocardial infarction. Int. J. Cardiol 2013; 167: 210–219.
14. Li D, Liu Y, Zhang X, et al. Inhibition of soluble epoxide hydrolase alleviated atherosclerosis by reducing monocyte infiltration in Ldlr(-/-) mice. J. Mol. Cell Cardiol 2016; 98: 128–137.
15. Tu R, Armstrong J, Lee KSS, et al. Soluble epoxide hydrolase inhibition decreases reperfusion injury after focal cerebral ischemia. Scientific reports 2018; 8(1): 5279.
16. Inceoglu B, Bettaieb A, Trindade da Silva CA, et al. Endoplasmic reticulum stress in the peripheral nervous system is a significant driver of neuropathic pain. Proc. Natl. Acad. Sci 2015; 112: 9082–9087.
17. Iyer A, Kauter K, Alam MA, et al. Pharmacological inhibition of soluble epoxide hydrolase ameliorates diet-induced metabolic syndrome in rats. Exp. Diabetes Res 2012; 758614.
18. Nakadera Y, Kunita K, Serizawa T, et al. Effect of Novel Soluble Epoxide Hydrolase Inhibitor Against to Pulmonary Arterial Hypertensive Rats. Journal of Cardiac Failure 2016; 22(9): S198.
19. Santos JM, Park JA, Joiakim A, et al. The role of soluble epoxide hydrolase in preeclampsia. Medical Hypotheses 2017; 108: 81–85.
20. Zhou Y, Chang HH, Du J, et al. Renal epoxyeicosatrienoic acid synthesis during pregnancy. AJP - Renal (2005); 288: 221-226.
21. Catella F, Lawson JA, Fitzgerald DJ, et al. Endogenous biosynthesis of arachidonic acid epoxides in humans: increased formation in pregnancy-induced hypertension. Proc Natl Acad Sci 1990; 87: 5893–5897.
22. Sari I, Pinarbasi H, Pinarbasi E, et al. Association between the soluble epoxide hydrolase gene and preeclampsia. Hypertension in pregnancy 2017; 36(4): 315-325.
23. American College of Obstetricians and Gynecologists. Report of the American College of Obstetricians and Gynecologists’ Task Force on Hypertension in Pregnancy. Obstet Gynecol 2013; 122 (5): 1122-31.
24. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis andvisualization of LD and haplotype maps. Bioinformatics 2005; 21( 2): 263-265
25. LaMarca B, Cornelius DC, Harmon AC, et al. Identifying immune mechanisms mediating the hypertension during preeclampsia. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology 2016; 311(1): R1-R9.
26. Tacconelli S, Patrignani P. Inside epoxyeicosatrienoic acids and cardiovascular disease. Frontiers in pharmacology 2014; 5: 239.
27. Jiang H, McGiff JC, Fava C, et al. Maternal and fetal epoxyeicosatrienoic acids in normotensive and preeclamptic pregnancies. Am J Hypertens 2013; 26 (2): 271–8.
28. Dai M, Wu L, Tu L, et al. The Immune-metabolic Regulatory Roles of Epoxyeicosatrienoic Acids on Macrophages Phenotypic Plasticity in Obesity-related Insulin Resistance. Prostaglandins & other lipid mediators 2018; 139: 36-40.
29. Plenty NL, Faulkner JL, Cotton J, et al. Arachidonic acid metabolites of CYP4A and CYP4F are altered in women with preeclampsia. Prostaglandins & other lipid mediators 2018; 136: 15-22.
30. Herse F, LaMarca B, Hubel CA, et al. Cytochrome P450 subfamily 2J polypeptide 2 expression and circulating epoxyeicosatrienoic metabolites in preeclampsia. Circulation 2012; 126(25): 2990-2999.
31. Decker M, Arand M, Cronin A. Mammalian epoxide hydrolases in xenobiyotic metabolism and signalling. Arch Toxicol 2009; 83: 297–318.
32. Zordoky BNM, El-Kadi AOS. Effect of cytochrome P450 polymorphism on arachidonic acid metabolism and their impact on cardiovascular diseases. Pharmacology & Therapeutics 2010; 125: 446–463.
33. Corenblum MJ, Wise VE, Georgi K, et al. Altered soluble epoxide hydrolase gene expression and function and vascular disease risk in the stroke-prone spontaneously hypertensive rat. Hypertension 2008; 51: 567-573.
34. Keserü B, Barbosa-Sicard E, Schermuly RT, et al. Hypoxia-induced pulmonary hypertension: comparison of soluble epoxide hydrolase deletion vs. inhibition. Cardiovascular Research 2010; 85: 232–240.
35. Zhang D, Ai D, Tanaka H, et al. DNA methylation of the promoter of soluble epoxide hydrolase silences its expression by an SP-1-dependent mechanism. BBA – Gene Regul Mech 2010; 1799: 659–67.
36. Sari I, Pınarbaşı H, Yıldız Ç. Epoxyeicosatrienoic acid Metabolism in Preeclampsia. Cumhuriyet Tıp Dergisi 2018; 40(4); 454-460.
Objavljeno
2020/08/27
Broj časopisa
Vol. 39 Br. 4 (2020): JMB
Rubrika
Original paper

Sva prava zadržana (c) 2020 İsmail Sarı

Creative Commons License

Ovaj rad je pod Creative Commons Autorstvo 4.0 međunarodnom licencom.

The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.

Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.